Renal osteodystrophy.
Patients with chronic renal failure often suffer from severe metabolic bone disease. This is usually either osteitis fibrosa cystica or osteomalacia. While parathyroidectomy is indicated in osteitis fibrosa cystica, desferrioxamine is an exciting new development in the treatment of osteomalacia.
D000535:Aluminum / Q000506:poisoning; D001706:Biopsy; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology; D002118:Calcium / Q000378:metabolism; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D004100:Dihydroxycholecalciferols / Q000378:metabolism; D006801:Humans; D006435:Renal Dialysis / Q000009:adverse effects; D014807:Vitamin D / Q000378:metabolism
D004100:Dihydroxycholecalciferols; D014807:Vitamin D; D000535:Aluminum; D002118:Calcium